For personal use only

ASX ANNOUNCEMENT **27 July 2020**

CardieX Completes $2.5 million Placement from New Strategic Investors

CardieX Limited (ASX: CDX) (CardieX, the Company) has successfully completed a $2.5 million placement offered to sophisticated investors at $0.03 per share with a 1 for 5 free attaching listed option (CDXO), resulting in the issue of approximately 83 million new Shares and 16.6 million new Listed Options (the **Placement**). Sixty Two Capital Pty Ltd acted as Lead Manager to the Placement.

The Company received strong demand from new sophisticated, wholesale and existing investors. In offering the Placement to new investors, the Company and Sixty Two Capital looked to identify groups with a long term view and alignment on the Company's strategic focus towards the development of its new product range.

New ordinary shares will be issued at an issue price of $0.03 per share with a 1 for 5 free attaching listed option (CDXO), that has an exercise price of $0.05. The share issue price of $0.03 represents a discount of less than 4% to the last traded price of CardieX prior to the Company's application for a trading halt.

The Company believes the Placement was competitively priced for both existing shareholders and the new incoming placement participants.

Commenting on the Placement, Craig Cooper, CardieX's Chief Executive Officer commented:

> *"We are pleased with the significant interest we received from sophisticated, and wholesale investors through this Placement, particularly during the current uncertain period, and that the placement has been well supported largely by new shareholders who have a shared vision for the strategic focus and unique opportunity of CardieX.*
>
> *It is pleasing to see this vision shared by new shareholders with a longer-term view of CardieX's value proposition. We now have a stronger share register with a wider representation, and a stronger balance sheet to take us forward through this period of scaling up our previously announced plans to move forward with our new product development program."*

In addition to the Placement, the Company announces its intention to shortly hold an Extraordinary General Meeting.

The Company will advise shareholders of the notice and timing of this meeting in due course. The primary business of the meeting will be to seek shareholder approval to ratify the placement of C2 Ventures Pty Ltd (related entity of Chairman Niall Cairn's and CEO Craig Cooper) of $500,000 in additional capital (previously announced in December 2019).

For personal use only

An indicative timetable for the completion of the Placement is below.

Event	Indicative Date
Announcement of Placement	Monday, 27 July 2020
Placement Settlement and Issue of Placement Shares	Friday, 31 July 2020
ASX Quotation of Placement Shares	Monday, 3 August 2020
Dispatch of Shareholder Statements for Placement Participants	Monday, 3 August 2020
Indicative timetable and is subject to change without notice. The Company reserves the right to vary the dates above, subject to any regulatory or statutory provisions that may apply.	

When combined with a current cash balance of ~$2.4m, the company is well funded to achieve its current milestones related to wearable technologies and new medical device developments.

The Placement funds will be applied towards working capital for the Company's existing operations and supporting the acceleration of the Company's previously announced new product development program.

ENDS.

Authorised for release by the full board of Directors, released by:

Jarrod White
Director

For more information please contact:

Investor Relations
Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au
Media Relations
Melissa Hamilton melissa.hamilton@mcpartners.com.au

About CardieX

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device (developed & marketed by 100% subsidiary ATCOR) is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.